



Genetic Pigmentary Disorders with Skin and Sensory Involvement in Paediatrics: A Comprehensive Review of the Management of Albinism

Dr Edwin Dias^{1,2*}, Thanshifa Fathima³

¹Professor and HOD, Department of Paediatrics, Srinivas Institute of Medical Sciences and Research Centre, Mangalore, Karnataka State, India.

²Adjunct Professor, Srinivas University, Director Of Research And Publication, India

³Final Year Pharm D, Srinivas College of Pharmacy, Valachil, Mangalore, Karnataka State, India.

DOI : <https://doi.org/10.55248/gengpi.07.0926.3010>

ABSTRACT

Genetic pigmentary disorders are a diverse group of genetically inherited diseases that present with a reduced or lack of melanin pigment production or distribution. Paediatric pigmentary diseases are often bilateral and present within the first decades of life and present within the skin, eyes, and the sense organs. Oculocutaneous albinism is one of the most prevalent paediatric pigmentary diseases with its link to visual impairment, photo-sensitivity, and the possibility of developing tumours within the skin. This review examines the genetic basis, pathogenesis, clinical patterns, diagnosis, and the current multi-disciplinary and holistic management of paediatric albinism. The review focuses on the role of the dermatological department, visual rehabilitation, pharmacologic therapy, genetic and psychological support.

Keywords: *Albinism, Paediatric pigmentary disorders, Oculocutaneous albinism, Visual impairment, Genetic disorders*

1. Introduction

The pigmentation of the skin, hair, and iris is dependent on the expression and function of melanocytes, which originate from the neural Crest cells in the early stages of human development¹. Genetic pigment aberrations result from melanin cell development, migration, melanosomal, or biosynthesis defects². Many patients with these conditions first show manifestations in childhood with potential long-term dermal, perceptual, and psychosocial consequences³.

When it comes to pigmentary conditions that affect children, albinism stands out because of the multiple systems that are affected by the condition. Albinism is characterized by the deficiency of melanin pigment of the skin, hair, and eyes, and it results in hypopigmentation and visual disturbances⁴. Albinism is associated with reduced visual acuity, nystagmus, photophobia, and refractive errors that have significant effects on the development of children⁵.

Secondly, aside from causing visual impairments, the absence of melanin makes one prone to damage and malignancies caused by ultraviolet radiation, especially if sun exposure is exceptionally high⁶. Also, because of the stigmatization and stress associated with this disease, early intervention is imperative⁷. This review aims to provide a comprehensive overview of paediatric albinism, focusing on current diagnostic and management strategies relevant to clinical pharmacy practice.

2. Classification of Genetic Pigmentary Disorders

Genetic pigmentary disorders are classified based on underlying pathogenic mechanisms⁸:

- Disorders of melanocyte number (piebaldism)
- Disorders of melanin synthesis (oculocutaneous albinism)
- Disorders of melanosome transport (Griscelli syndrome)
- Syndromic pigmentary disorders with sensory involvement (Waardenburg syndrome, Hermansky-Pudlak syndrome)⁹⁻¹¹

3. Genetics and Pathophysiology of Albinism

- Oculocutaneous albinism is typically inherited in an autosomal recessive manner and results from mutations in genes responsible for melanin biosynthesis¹². The major subtypes include OCA1 (TYR gene), OCA2 (OCA2 gene), OCA3 (TYRP1 gene), and OCA4 (SLC45A2 gene)^{13–15}.
- Defective tyrosinase activity leads to impaired conversion of tyrosine to melanin, resulting in hypopigmentation¹⁶. Melanin deficiency during ocular development causes abnormal retinal maturation and misrouting of optic nerve fibers, leading to characteristic visual defects¹⁷.

4. Clinical Manifestations

4.1 Cutaneous Features

- The skin manifestations may include generalized skin and hair hypopigmentation. The lowered melanin production makes patients more susceptible to sunlight, sunburn, and non-melanoma skin cancers¹⁸.

4.2 Ocular and Sensory Involvement

- The ocular manifestations are decreased visual acuity, nystagmus, photophobia, strabismus, and refractive errors¹⁹.
- Foveal hypoplasia is a critical diagnostic criterion, as it correlates well with the visual severity²⁰.
- Syndromic pigmentary disorders such as Waardenburg and Tietz syndromes may present with sensorineural hearing loss^{21–23}.

5. Diagnostic Evaluation

- Diagnosis is primarily clinical and supported by ophthalmologic examination and genetic testing²⁴. Optical coherence tomography is useful for assessing foveal hypoplasia²⁵.

6. Management of Albinism in Paediatrics

6.1 Dermatological Management

- Strict photoprotection including sunscreen use, protective clothing, and sun avoidance is essential²⁶. Regular dermatologic surveillance is recommended²⁷.

6.2 Visual Rehabilitation

- Management includes refractive correction, low-vision aids, tinted lenses, and amblyopia therapy when required^{28–30}.

6.3 Pharmacological Considerations

- Although no curative pharmacotherapy exists, pharmacists play an important role in counselling on sunscreen use, vitamin D supplementation, and medication safety³¹.

6.4 Genetic Counselling

- Genetic counselling helps families understand inheritance patterns and recurrence risks³².

6.5 Psychosocial Support

- Psychological support and educational accommodations are crucial in improving quality of life^{33–34}.

7. Summary

Genetic pigmentary disorders constitute a heterogeneous group of inherited conditions that mainly involve melanocyte function, melanin synthesis, or distribution and often present early in childhood. Among these, oculocutaneous albinism represents one of the most clinically important due to its multisystem involvement: dermatological, ocular, and psychosocial aspects. A congenital absence or deficiency of melanin results in typical

hypopigmentation of the skin, hair, and eyes and visual disturbances that may considerably disable daily functioning and performance at school in paediatric patients.

This review highlights the genetic basis and pathophysiology of albinism, emphasizing defects in key genes such as *TYR*, *OCA2*, *TYRP1*, and *SLC45A2*, which disrupt melanin biosynthesis and normal ocular development. The resulting abnormalities in retinal maturation and optic nerve routing account for the visual deficits commonly observed in affected children. Additionally, the lack of melanin-mediated photoprotection significantly increases susceptibility to ultraviolet radiation damage, placing children with albinism at a higher lifetime risk of actinic skin damage and non-melanoma skin cancers.

Management of paediatric albinism requires a multidisciplinary approach. Dermatological care includes rigorous photoprotection and early detection of skin malignancies, and ophthalmologic interventions are carried out with the aim of optimization of visual function through refractive correction, low-vision aids, and early visual rehabilitation. Genetic counselling is indispensable in educating families on the mode of inheritance, recurrence risks, and reproductive options. Likewise, psychosocial and educational interventions are important for countering stigma, improving self-esteem, and promoting social inclusion. Collectively, early diagnosis coupled with comprehensive care can significantly reduce morbidity and enhance long-term outcomes of children with albinism.

8. Recommendations

1. Early diagnosis and routine screening
2. Lifelong photoprotection education
3. Regular ophthalmologic and dermatologic follow-up
4. Genetic counselling for affected families
5. Psychosocial and educational support
6. Continued research into gene-based therapies

9. Conclusion

Albinism is a congenital genetic condition that has been associated with medical, visual, and psychological challenges, especially when it occurs at a childhood stage. Even though there is no permanent treatment for this condition, an earlier detection and intervention program has been seen to greatly limit preventable complications associated with this condition. Technological improvements have been evidenced through genetic testing and evaluation of the eye.

Holistic and interdisciplinary care remains the hallmark of its successful management. The intersection of dermatological care, visual rehabilitation, pharmacological consulting, genetic advising, and psychosocial care remains paramount. The role of clinical pharmacists and other professionals cannot be overstated in patient teaching, the role of photoprotection and vitamins in the prevention of complications, and the role of these measures in the long-term management. Moreover, the social stigma and need for adaptation in education remains critical in maximizing the benefits of optimal socialization in children.

Ongoing research into the molecular mechanisms of albinism and emerging gene-based therapies offers promising prospects for future disease-modifying treatments. Until such therapies become clinically available, strengthening awareness, early screening programs, and multidisciplinary care pathways will remain critical in minimizing disease burden. Ultimately, a patient-centred, comprehensive approach can empower children with albinism to lead healthier, more productive, and socially inclusive lives.

References:

1. Nordlund JJ, Boissy RE, Hearing VJ. The pigmentary system. Oxford: Oxford University Press; 2006.
2. Spritz RA. The genetics of generalized vitiligo and associated autoimmune diseases. *J Dermatol Sci*. 2012;66(1):3–9.
3. Grønskov K, Ek J, Brøndum-Nielsen K. Oculocutaneous albinism. *Orphanet J Rare Dis*. 2007;2:43.
4. Read AP, Newton VE. Waardenburg syndrome. *J Med Genet*. 1997;34(8):656–65.
5. King RA, Oetting WS, Summers CG. Albinism. *Lancet*. 2007;370(9603):195–206.
6. Summers CG. Vision in albinism. *Trans Am Ophthalmol Soc*. 1996;94:1095–155.
7. Bradford PT. Skin cancer in albinism. *J Am Acad Dermatol*. 2009;60(4):571–8.
8. Lund PM. Health and education of children with albinism. *Dev Med Child Neurol*. 2001;43(11):782–9.
9. Orlow SJ. Pigmentary disorders. *Dermatol Clin*. 2005;23(2):257–67.

10. Griscelli C, Durandy A. Immunodeficiency with hypopigmentation. *Am J Med.* 1978;65(4):691–702.
11. Hermansky F, Pudlak P. Albinism with hemorrhagic diathesis. *Blood.* 1959;14:162–9.
12. Pingault V, Ente D, Dastot-Le Moal F. Auditory-pigmentary syndromes. *Hum Genet.* 2010;128(5):453–71.
13. Oetting WS. The tyrosinase gene and albinism. *Pigment Cell Res.* 2000;13(5):320–5.
14. Hutton SM, Spritz RA. Comprehensive analysis of OCA2. *Am J Hum Genet.* 2008;82(2):308–17.
15. Rooryck C, Morice-Picard F. OCA4 review. *Eur J Hum Genet.* 2008;16(1):29–35.
16. Simeonov DR, Wang X. Advances in albinism genetics. *Genet Med.* 2013;15(9):689–97.
17. Hearing VJ. Biogenesis of melanosomes. *J Invest Dermatol.* 2005;125(4):641–6.
18. Jeffery G. Developmental anomalies in albinism. *Eye.* 1997;11(2):217–23.
19. Hong ES, Zeeb H. Clinical spectrum of albinism. *Pediatr Dermatol.* 2006;23(5):405–10.
20. Lookingbill DP, Lookingbill GL. Actinic damage in albinism. *Arch Dermatol.* 1995;131(12):1441–6.
21. Abadi RV, Pascal E. Visual deficits in albinism. *Vision Res.* 1991;31(5):915–20.
22. Thomas MG, Kumar A. Foveal hypoplasia grading. *Ophthalmology.* 2011;118(8):1653–60.
23. Tietz W. A syndrome of deaf-mutism and albinism. *Am J Hum Genet.* 1963;15:259–64.
24. Sheth V, Reddy S. Waardenburg syndrome. *Indian J Dermatol.* 2012;57(6):476–9.
25. Pingault V. Melanocyte-related deafness. *Hum Mol Genet.* 2018;27(R2):R120–9.
26. Orlow SJ. Diagnostic evaluation of hypopigmentation. *Dermatol Clin.* 2010;28(3):427–38.
27. McAllister JT. OCT in albinism. *Invest Ophthalmol Vis Sci.* 2010;51(12):6601–8.
28. Green AC. Sunscreen and photoprotection. *Lancet.* 1999;354(9180):723–9.
29. Kromberg JG. Cancer risk in albinism. *S Afr Med J.* 2013;103(10):663–4.
30. Chiang MF. Pediatric low vision rehabilitation. *Pediatrics.* 2015;136(1):e201–8.
31. Weiss AH. Amblyopia therapy. *Ophthalmology.* 2006;113(2):348–56.
32. Carden SM. Visual aids in albinism. *Clin Exp Optom.* 2012;95(1):54–9.
33. Holick MF. Vitamin D deficiency. *N Engl J Med.* 2007;357(3):266–81.
34. Biesecker LG. Genetic counseling. *N Engl J Med.* 2002;347(19):1553–60.
35. Franklin A. Social aspects of albinism. *Soc Sci Med.* 2010;71(6):1031–9.
36. Marçal N. Future therapies in albinism. *Exp Eye Res.* 2020;201:108300.